Funder
Unitaid
Agence Nationale de Recherches sur le Sida et les Hépatites Virales
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference39 articles.
1. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV [Internet]. Geneva: World Health Organization; 2018. Report No.: WHO/CDS/HIV/18.51. Available from: http://www.who.int/hiv/pub/guidelines/ARV2018update/en/.
2. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403–12.
3. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.
4. World Health Organization. Statement on DTG—Geneva 18 May 2018 [Internet]. Geneva: World Health Organization; 2018. Available from: https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf.
5. Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018;13:102–11.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献